NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Baxdrostat for treating uncontrolled or resistant hypertension ID6623

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company • Astra Zeneca (baxdrostat) Patient/carer groups • Arrhythmia Alliance • Blood Pressure UK • British Cardiovascular Society • Cardiovascular Care Partnership • Circulation Foundation • Different Strokes • Heart UK • Kidney Care UK • Kidney Research UK • National Kidney Federation • Network of Sikh Organisations • Pulmonary Hypertension Association UK • Pumping Marvellous Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Stroke Association • Stroke Information • Sue Ryder Healthcare professional groups • Association of Renal Technologists • British and Irish Association of Stroke Physicians • British and Irish Hypertension Society • British Association of Urological Nurses • British Geriatrics Society • British Heart Foundation • British Society for Haematology • British Society for Haemostasis and Thrombosis • British Society for Heart Failure	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Association of Renal Industries • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health - Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • NHS Wales Joint Commissioning Committee • Scottish Medicines Consortium • Welsh Government Possible comparator companies None Relevant research groups • British Society for Cardiovascular Research • Cochrane Heart, Stroke and Circulation • Cochrane Hypertension Group • Cochrane Kidney and Transplant Group • Cochrane Stroke Group • European Council for Cardiovascular Research • Genomics England • Heart Research UK • MRC Clinical Trials Unit

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
• British Society of Cardiovascular Imaging • Clinical Leaders of Thrombosis (CLOT) • National Heart and Lung Institute • Primary Care Cardiovascular Society • Royal College of Emergency Medicine • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science and Technology • Society for DGH Nephrologists • Society for Vascular Nurses • Society for Vascular Technology • UK Clinical Pharmacy Association • UK Kidney Association • UK Renal Pharmacy Group • Vascular Society of Great Britain and Ireland <u>Others</u> • Department of Health and Social Care • NHS England	• National Centre for Cardiovascular Preventions and Outcomes • National Institute for Health Research • The Society for Research in Rehabilitation • Wellcome Trust <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

